home / stock / rfl / rfl news

RFL News and Press, Rafael Holdings Inc. Class B From 10/20/20

Stock Information
Company Name: Rafael Holdings Inc. Class B
Stock Symbol: RFL
Market: NYSE
Website: rafaelholdings.com
Menu
RFL RFL Quote RFL Short RFL News RFL Articles RFL Message Board
Get RFL Alerts

News, Short Squeeze, Breakout and More Instantly...
RFL - A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan

CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its partner Ono Pharmaceutical Co., Ltd. (“Ono”...
RFL - LD Micro - 360 Companies Set to Present - this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

RFL - Rafael Holdings to Present at LD Micro Investor Conference

NEWARK, N.J. , Aug. 24, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), today announced that it will present at The LD 500 Virtual Conference on Thursday, September 3, 2020 . David Polinsky , Rafael's Chief Financial Officer, will discuss the company's unique port...

RFL - Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®? (devimistat) for Patients with Metastatic Pancreatic Cancer

CRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has reached its target enrollment of 500 patients in its p...
RFL - Tracking Kahn Brothers Portfolio - Q2 2020 Update

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 08/04/2020. Please visit our Tracking Kahn Brothers Portfolio series t...

RFL - Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cranbury, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Rafafel_Pharma_PHP_Graphic_Updated_V3 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has crossed the mi...

RFL - Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Cranbury, NJ, May 26, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the positive results of a single-arm, open-label, Phase 1 study ...
RFL - Tracking Kahn Brothers Portfolio - Q1 2020 Update

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 05/11/2020. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...

RFL - The Barer Institute Signs LOI for Lab Space at 3.0 University Place in Philadelphia

PHILADELPHIA , May 12, 2020 /PRNewswire/ -- The Barer Institute Inc. a subsidiary of Rafael Holdings, Inc. (NYSE: RFL) and University Place Associates (UPA) have announced that The Barer Institute has signed a non-binding Letter of Intent to lease Growth Pod space at 3.0 University P...

RFL - Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models

Cranbury, NJ, May 07, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has entered into a research collaboration with a major medica...
Previous 10 Next 10